Payment overview · 2025
General Payments
$3,708.78
46 reported records · 10 companies
Healthcare provider profile · identity verified
Manuel Munoz Reyes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · HOUSTON, TX · NPI 1891069050
Verified facts
What the public records show
CMS Open Payments records show Manuel Munoz Reyes, M.D. received $3,708.78 in general payments during 2025 across 46 reported records.
Abbott Laboratories accounted for 42.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,567.49 | 42.3% | 22 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $1,287.92 | 34.7% | 11 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $248.33 | 6.7% | 3 | 2025 |
| Elutia, Inc. | Unresolved — no canonical attribution shown | $166.85 | 4.5% | 1 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $132.35 | 3.6% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $115.81 | 3.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $84.83 | 2.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $46.82 | 1.3% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $31.09 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.29 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,035.64 | 39 |
| Travel and Lodging | $1,048.14 | 6 |
| Consulting Fee | $625.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $1,136.03 | 10 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $625.00 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $320.71 | 6 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $248.33 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $227.96 | 7 | 2025 |
Source payment records
|
|||||
| ECM Patch,Pouch Normalized: ecm patch pouch |
Device | Elutia, Inc. | $166.85 | 1 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $132.35 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $45.06 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $31.09 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $31.09 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $30.37 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $12.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 222 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
222 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 97 |
| Carvedilol | Carvedilol | 274 | 74 |
| Losartan Potassium | Losartan Potassium | 225 | 68 |
| Eliquis | Apixaban | 222 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 186 | 56 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 180 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 41 |
| Furosemide | Furosemide | 130 | 40 |
| Repatha Sureclick | Evolocumab | 102 | 23 |
| Nifedipine Er | Nifedipine | 100 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 20 |
| Lisinopril | Lisinopril | 82 | 24 |
| Ezetimibe | Ezetimibe | 67 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 19 |
| Multaq | Dronedarone Hcl | 66 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 15 |
| Chlorthalidone | Chlorthalidone | 57 | 16 |
| Nitroglycerin | Nitroglycerin | 55 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 16 |
| Xarelto | Rivaroxaban | 47 | 13 |
| Prasugrel Hcl | Prasugrel Hcl | 41 | suppressed |
| Praluent Pen | Alirocumab | 39 | 11 |
| Valsartan | Valsartan | 38 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 37 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | 12 |
| Repatha Syringe | Evolocumab | 31 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,708.78 · 46 records | Abbott Laboratories | ACCOLADE SR, ASSURITY, AURYON LASER SYSTEM 100-120 VAC, BioMimics 3D Vascular Stent System, CARDIOMEMS, ECM Patch,Pouch, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, ENDOCROSS Device, FARXIGA, GALLANT, General - Therapies, JOT DX, LUX-Dx Insertable Cardiac Monitor, MERLIN@HOME, SAPIEN 3 Ultra RESILIA, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRICLIP, Torus Stent Graft System | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error